Price quotes for Zetia from multiple providers

The controversy surrounding the highly promoted cholesterol-lowering drug Vytorin continued Friday when U.S. health officials said they would review the medication’s effectiveness, but only after final trial results were completed.
a combination of two cholesterol drugs — had little medical benefit.
“We have not yet received a final study report and can’t explain why Vytorin didn’t lead to lesser amounts of plaque compared to patients treated with simvastatin alone,” Dr. Jo…